SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Advaxis, Inc. (ADXS)

Blue, there's no doubt in my mind that

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
hdwrsft Member Profile
 
Followed By 5
Posts 1,366
Boards Moderated 0
Alias Born 07/14/16
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/25/2017 4:55:48 PM
Biotech's Recently Under the Microscope, Analyst Coverage "InvestorsHub NewsWire" - 9/20/2017 8:00:00 AM
Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference "Business Wire" - 9/18/2017 9:02:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 9/11/2017 4:34:01 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 9/11/2017 4:07:05 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/5/2017 4:31:58 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/5/2017 4:31:58 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/1/2017 4:33:09 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/1/2017 4:32:40 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/21/2017 5:02:24 PM
Initial Statement of Beneficial Ownership (3) "Edgar (US Regulatory)" - 7/12/2017 5:31:49 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/7/2017 6:04:08 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:33:21 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:32:55 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 7/3/2017 4:32:24 PM
Advaxis’ Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017 "Business Wire" - 6/26/2017 8:55:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:32:13 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:31:48 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 6/20/2017 6:31:48 PM
Advaxis to Present at 2017 BIO International Convention "Business Wire" - 6/16/2017 8:00:00 AM
Advaxis to Be Featured on Worldwide Business with kathy ireland® "Business Wire" - 6/14/2017 8:00:00 AM
Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day "Business Wire" - 6/13/2017 12:30:00 PM
Advaxis to Webcast Investor & Analyst Day 2017 "Business Wire" - 6/9/2017 8:00:00 AM
Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available "Business Wire" - 6/8/2017 9:17:00 AM
Advaxis to Present at Jefferies 2017 Global Healthcare Conference "Business Wire" - 6/7/2017 8:30:00 AM
hdwrsft   Tuesday, 11/15/16 06:52:01 PM
Re: blueyedcatch post# 8268
Post # of 35838 
Blue, there's no doubt in my mind that the deal wheel will be spinning, IMO.

For example, On September 28, 2016, Pfizer (PFE) announced the completion of its acquisition of Medivation for around $14 billion. This deal has added leading metastatic prostate cancer drug Xtandi to Pfizer’s oncology portfolio.

14Bil!!! Holy moly!

Well, guess what, we'll have prostate data next quarter on top of GOG full data presentation AND an ADXS-NEO IND (Will that trigger a milestone payment??)


Next month:
-----------

Preclinical data presentation (ImVACS, December 2016)


Calendar Q1-2017:
-----------------

(Cervical) GOG-0265 full data presentation – (1H 2017)
(Prostate) Preliminary data from ADXS-PSA + pembrolizumab cohorts A + B (1H 2017)
(NEO) ADXS-NEO Active IND (1H 2017)


Calendar Q2-2017:
-----------------
(Cervical plus Head&Neck) AXAL + durvalumab cervical/head & neck – updated data (2H 2017)
(AnalCancer) FAWCETT Stage 1 data (2H 2017)


ASCO 2017 - June 2-6, 2017 Chicago, Illinois:
---------------------------------------

(Anal) Ph 2 BrUOG – 11 patients update (ASCO 2017*)
(Head&Neck) Mt Sinai/Baylor Ph 2 Head & Neck (ASCO 2017*)
(Pediatric Osteosarcoma) COG study in pediatric osteosarcoma study start (1H 2017) • Preliminary Phase 1 data (ASCO 2017*)


Q1/Q2-2018:
-----------

(Prostate) ADXS-PSA + pembrolizumab – complete enrollment of expansion cohort
(Q4 2017); data (1H 2018)


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist